IMC-001

IMC-001 (STI-3031) is a monoclonal antibody (fully human IgG1) from ImmuneOncia Therapeutics, with Sorrento Therapeutics as registered STI-3031 (other name IMC-001) trials. A fully human IgG1 antibody against PD-L1 that blocks PD-1/PD-L1 binding and also triggers antibody-dependent cellular cytotoxicity by NK cells. Its furthest stage is phase 2, for extranodal NK/T-cell lymphoma, nasal type, TMB-high solid tumours and resectable gastric, oesophageal and liver cancer (investigator neoadjuvant study). ClinicalTrials.gov registers it in 5 studies linked below. Whether it works in people has not been established unless a trial below reports it.